Last reviewed · How we verify
NCT05655819
A Study of Glutamine to Treat Intestinal Permeability in Functional Dyspepsia
Phase 1, PHASE2 trial testing Glutamine in Functional Dyspepsia in 12 participants. Completed in 31 December 2025.
31 December 2025
Quick facts
| Lead sponsor | David J. Cangemi |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 12 |
| Start date | 16 February 2023 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Glutamine (GLUTAMINE) — full drug profile →
- Placebo
Conditions studied
- Functional Dyspepsia — all drugs for Functional Dyspepsia →
Sponsor
David J. Cangemi
Who can join
Adults 18 to 75, any sex, with Functional Dyspepsia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this research is to collect data from patients diagnosed with functional dyspepsia who are treated with glutamine and describe safety and treatment results compared to patients taking a placebo. Glutamine, an essential amino acid in humans, is an important energy source for cells lining the gastrointestinal tract and has been shown to play an important role in regulating the strength of the intestinal wall.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05655819
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Glutamine
Trials testing the same drug.
- NCT06617182 — Efficacy and Safety of Thalidomide Combined With Glutamine in the Treatment of Radiation Intestinal Injury. · Phase 2 · recruiting
- NCT05569993 — Glutamine and Traumatic Brain Injury · EARLY_PHASE1 · unknown
- NCT05856188 — Efficacy of Glutamine in Management of Radiation Mucositis · NA · unknown
- NCT04909905 — Glutamine Supplementation and Short-term Mortality in Covid-19 · Phase 3 · completed
- NCT04388371 — Glutamine PET Imaging in LAM · Phase 1 · completed
Other recruiting trials for Functional Dyspepsia
Currently open trials in the same condition.
- NCT07442734 — Auricular Stimulation for Functional Dyspepsia With Insomnia: Efficacy and Mechanisms · NA · recruiting
- NCT07250308 — Correlation Study of Atrophic Gastritis and Dyspepsia Symptoms · recruiting
- NCT07187492 — Efficacy of Bacillus Coagulans in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia · Phase 4 · recruiting
- NCT07182890 — Efficacy of Clostridium Butyricum in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia · Phase 4 · recruiting
- NCT07210294 — Press Needle on Body Acupuncture Points and Auricular Acupuncture Points on Functional Dyspepsia · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05655819 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by David J. Cangemi
- Last refreshed: 3 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05655819.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing